Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

2023469 citationsJournal Articlegreen Open Access

Authors

Pieter Sonneveld · Erasmus MC Cancer Institute

Meletios Α. Dimopoulos · National and Kapodistrian University of Athens

Mario Boccadoro · Azienda Ospedaliera Citta' della Salute e della Scienza di Torino

Hang Quach · St. Vincent's Birmingham

P. Joy Ho · The University of Sydney

Meral Beksaç · Ankara University

Cyrille Hulin

Abstract

The addition of subcutaneous daratumumab to VRd induction and consolidation therapy and to lenalidomide maintenance therapy conferred a significant benefit with respect to progression-free survival among transplantation-eligible patients with newly diagnosed multiple myeloma. (Funded by the European Myeloma Network in collaboration with Janssen Research and Development; PERSEUS ClinicalTrials.gov number, NCT03710603; EudraCT number, 2018-002992-16.).

Topics & Keywords

Multiple Myeloma Research and Treatments Protein Degradation and Inhibitors Research on Leishmaniasis Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 390, Issue 4, pp. 301-313

DOI: 10.1056/nejmoa2312054

Field-Weighted Citation Impact: 135.40